Annovis Bio (ANVS) Cash & Equivalents (2019 - 2026)

Annovis Bio has reported Cash & Equivalents for 8 years, with the latest figure at $14.2 million in Q1 2026.

• Quarterly Cash & Equivalents fell 36.14% year-over-year to $14.2 million in Q1 2026, while the trailing twelve-month figure through Mar 2026 was $14.2 million (down 36.14% YoY) and the FY2025 annual result came in at $19.5 million, up 85.11% from the prior year.
• Cash & Equivalents eased to $14.2 million in Q1 2026 per ANVS's latest filing, from $19.5 million in the prior quarter.
• Over five years, Cash & Equivalents peaked at $42.7 million in Q1 2022 and troughed at $3.1 million in Q1 2024.
• A 5-year average of $17.6 million and a median of $15.7 million in 2023 frame the typical range for Cash & Equivalents.
• The sharpest annual moves came in 2022 and 2023: Cash & Equivalents soared 661.56% in 2022, then slumped 87.89% in 2023.
• Over 5 years, Cash & Equivalents stood at $28.4 million in 2022, then sank by 79.72% to $5.8 million in 2023, then soared by 83.36% to $10.6 million in 2024, then soared by 85.11% to $19.5 million in 2025, then decreased by 27.3% to $14.2 million in 2026.
• According to Business Quant data, Cash & Equivalents over the past three periods registered $14.2 million, $19.5 million, and $15.3 million for Q1 2026, Q4 2025, and Q3 2025 respectively.